F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03501940|
Expanded Access Status : No longer available
First Posted : April 18, 2018
Last Update Posted : January 21, 2022
|First Submitted Date||April 10, 2018|
|First Posted Date||April 18, 2018|
|Last Update Posted Date||January 21, 2022|
|Brief Title||F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer|
|Brief Summary||This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.|
I. To evaluate fluorine F 18 DCFPyL (18F-DCFPyL) PET/CT for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA).
Participants receive fluorine F 18 DCFPyL intravenously (IV). After 60-120 minutes, participants undergo whole body PET/CT. Immediately after the first scan, participants may undergo a second PET/CT without receiving fluorine F 18 DCFPyL.
After completion of study, participants are followed up at 24-72 hours.
|Study Type||Expanded Access|
|Expanded Access Type||Intermediate-size Population|
|Publications *||Baratto L, Song H, Duan H, Hatami N, Bagshaw HP, Buyyounouski M, Hancock S, Shah S, Srinivas S, Swift P, Moradi F, Davidzon G, Iagaru A. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2021 Nov;62(11):1545-1549. doi: 10.2967/jnumed.120.259630. Epub 2021 Mar 5.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Expanded Access Status||No longer available|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||United States|
|Removed Location Countries|
|Current Responsible Party||Andrei Iagaru, Stanford University|
|Original Responsible Party||Same as current|
|Current Study Sponsor||Andrei Iagaru|
|Original Study Sponsor||Same as current|
|PRS Account||Stanford University|
|Verification Date||January 2022|